Earnings Release • Jan 26, 2023
Earnings Release
Open in ViewerOpens in native device viewer


(compared with the corresponding period a year ago)
| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 156,173 | 121,867 | 28 | 43,834 | 34,226 | 28 |
| Adjusted operating profit before amortization of acquisition related intangible assets (EBITA)1 |
13,058 | 13,680 | -5 | 4,084 | 3,077 | 33 |
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
10,887 | 14,051 | -23 | 3,790 | 3,004 | 26 |
| Amortization of acquisition-related intangible assets | -1,116 | -852 | -290 | -250 | ||
| Adjusted operating profit1 | 11,942 | 12,828 | -7 | 3,794 | 2,827 | 34 |
| Items affecting comparability | -2,463 | 371 | -323 | -73 | ||
| Operating profit | 9,479 | 13,199 | -28 | 3,471 | 2,754 | 26 |
| Financial items | -1,370 | -662 | -570 | -190 | ||
| Profit before tax | 8,109 | 12,537 | -35 | 2,901 | 2,564 | 13 |
| Adjusted profit before tax1 | 10,572 | 12,166 | -13 | 3,224 | 2,637 | 22 |
| Income taxes | -2,045 | -2,727 | -655 | -346 | ||
| Profit for the period | 6,064 | 9,810 | -38 | 2,246 | 2,218 | 1 |
| Earnings per share, SEK | 7.93 | 12.27 | 3.15 | 2.82 | ||
| Adjusted earnings per share, SEK2 | 12.28 | 12.50 | 3.78 | 3.14 |
1Excluding items affecting comparability; for amounts see page 13.
2Excluding items affecting comparability and amortization of acquisition-related intangible assets.

"In 2022, Essity achieved record growth and its highest net sales ever. We can see that, despite significant cost inflation, we achieved an operating profit, before depreciation, amortization and impairment, that was in line with 2021. We implemented significant price increases, while volumes were higher for the year."
Essity's net sales for 2022 amounted to approximately SEK 156bn. Sales growth, including organic sales growth and acquisitions, was strong and amounted to 17.7% and the average price increase was 13.3%. Sales growth was strong in all three business areas: Health & Medical, Consumer Goods and Professional Hygiene, which are all leading in a growing global hygiene and health market. Despite significant price increases, volumes were higher for the year. Work to improve efficiency has progressed at a high pace. Adjusted EBITA amounted to SEK 13,058m and the adjusted EBITA margin to 8.4%.
The adjusted return on capital employed was 9.7%. Earnings per share were SEK 7.93. For the 2022 fiscal year, the Board of Directors proposes an increase in the dividend of 4% to SEK 7.25 per share.
The year was dominated by the war in Ukraine and the resulting human suffering. Essity has made donations to the UNHCR and other international and local organizations. Work is ongoing to exit the Russian market and the company's assets in Russia have been impaired by approximately SEK 1.7bn.
In the fourth quarter, net sales increased significantly and amounted to approximately SEK 44bn. Further price increases were implemented and averaged 18.4%, an increase of 6% compared with the third quarter 2022. As a result of our successful work to raise prices, adjusted EBITA increased 33% and the adjusted EBITA margin increased 0.3 of a percentage point to 9.3%. Compared with the third quarter of 2022, the adjusted EBITA margin increased 1.8 percentage points. The adjusted return on capital employed increased to 11.4%.
Three companies were acquired, in line with our strategy to grow in segments with strong future growth. The acquisition of the US company Legacy Converting Inc. will broaden Essity's offering in Professional Hygiene through a stronger position in wiping and cleaning products in the North American market. Two leading companies were acquired in Intimate Hygiene: Knix Wear Inc. and Modibodi. Essity is now a global market leader1) within leakproof apparel, which is the fastest growing product segment in Intimate Hygiene.
We continued to invest in innovation and marketing to increase the share of premium offerings, sustainable solutions and digital offerings. In 2022, Essity's e-commerce sales increased by 20% to SEK 23bn, corresponding to 15% of net sales. We also increased the company's direct-to-consumer sales through investments and acquisitions.
1) Estimate based on market data compiled by Essity

Leadership in the area of sustainability is a strategic priority for Essity to increase sales and profitability and to reduce risk in the company while we contribute toward a better world. For example, we have launched toilet paper containing wheat straw-based pulp under the Zewa brand and the Libero Touch climate-smart baby diaper. The company's carbon emissions under Science Based Targets, Scope 1 and 2, have been reduced by 18% compared with 2016. Essity also received several awards for the company's sustainability work, for example it was named as one of the world's most sustainable companies by Corporate Knights, has been included in S&P Global's Sustainability Yearbook 2022 as one of the top 150 most sustainable companies and CDP recognized Essity for leadership in sustainability, including us on its A-list for our work to combat deforestation. For the second consecutive year, we were designated a Diversity Leader by the Financial Times in its annual review of diversity work in European companies.
In order to achieve the Group's long-term targets with respect to growth and return by 2025, Essity is prioritizing innovation, strong brands, efficiency improvements and sustainability. We continue to work with price increases to offset cost inflation. Growth in the fastest growing sales channels and regions as well as in segments with the highest returns will be prioritized to create long-term growth in value for customers, consumers, employees and shareholders.
Magnus Groth President and CEO

| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 156,173 | 121,867 | 28 | 43,834 | 34,226 | 28 |
| Cost of goods sold | -117,046 | -86,628 | -32,499 | -25,617 | ||
| Items affecting comparability - cost of goods sold | -1,899 | -146 | -302 | -82 | ||
| Gross profit | 37,228 | 35,093 | 6 | 11,033 | 8,527 | 29 |
| Adjusted gross profit1 | 39,127 | 35,239 | 11 | 11,335 | 8,609 | 32 |
| Sales, general and administration | -26,107 | -21,617 | -7,259 | -5,538 | ||
| Items affecting comparability - sales, general and administration | -272 | 517 | 8 | 9 | ||
| Share of profits of associates and joint ventures | 38 | 58 | 8 | 6 | ||
| Operating profit before amortization of acquisition-related intangible assets (EBITA) |
10,887 | 14,051 | -23 | 3,790 | 3,004 | 26 |
| Adjusted operating profit before amortization of acquisition-related intangible assets (EBITA)1 |
13,058 | 13,680 | -5 | 4,084 | 3,077 | 33 |
| Amortization of acquisition-related intangible assets | -1,116 | -852 | -290 | -250 | ||
| Items affecting comparability – acquisition-related intangible assets | -292 | 0 | -29 | 0 | ||
| Operating profit | 9,479 | 13,199 | -28 | 3,471 | 2,754 | 26 |
| Adjusted operating profit1 | 11,942 | 12,828 | -7 | 3,794 | 2,827 | 34 |
| Financial items | -1,370 | -662 | -570 | -190 | ||
| Profit before tax | 8,109 | 12,537 | -35 | 2,901 | 2,564 | 13 |
| Adjusted profit before tax1 | 10,572 | 12,166 | -13 | 3,224 | 2,637 | 22 |
| Income taxes | -2,045 | -2,727 | -655 | -346 | ||
| Profit for the period | 6,064 | 9,810 | -38 | 2,246 | 2,218 | 1 |
| Adjusted profit for the period1 1 Excluding items affecting comparability |
8,327 | 9,363 | -11 | 2,490 | 2,264 | 10 |
| Tax on amortization of acquisition-related intangible assets | 320 | 245 | 86 | 72 | ||
| Margins (%) Gross margin |
23.8 | 28.8 | 25.2 | 24.9 | ||
| Adjusted gross margin1 | 25.1 | 28.9 | 25.9 | 25.2 | ||
| EBITA margin | 7.0 | 11.5 | 8.6 | 8.8 | ||
| Adjusted EBITA margin1 | 8.4 | 11.2 | 9.3 | 9.0 | ||
| Operating margin | 6.1 | 10.8 | 7.9 | 8.0 | ||
| Adjusted operating margin1 | 7.6 | 10.5 | 8.7 | 8.3 | ||
| Financial net margin | -0.9 | -0.5 | -1.3 | -0.6 | ||
| Profit margin | 5.2 | 10.3 | 6.6 | 7.4 | ||
| Adjusted profit margin1 | 6.7 | 10.0 | 7.4 | 7.7 | ||
| Income taxes | -1.3 | -2.2 | -1.5 | -1.0 | ||
| Adjusted income taxes1 | -1.4 | -2.3 | -1.7 | -1.1 | ||
| Net margin | 3.9 | 8.1 | 5.1 | 6.4 | ||
| Adjusted net margin1 | 5.3 | 7.7 | 5.7 | 6.6 |
1Excluding items affecting comparability

| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Health & Medical | 2,903 | 3,821 | -24 | 721 | 927 | -22 |
| Consumer Goods | 7,211 | 7,938 | -9 | 2,245 | 1,666 | 35 |
| Professional Hygiene | 3,998 | 2,710 | 48 | 1,423 | 681 | 109 |
| Other | -1,054 | -789 | -305 | -197 | ||
| Total1 | 13,058 | 13,680 | -5 | 4,084 | 3,077 | 33 |
1Excluding items affecting comparability; for amounts see page 13.
| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Health & Medical | 2,054 | 3,101 | -34 | 500 | 737 | -32 |
| Consumer Goods | 6,964 | 7,815 | -11 | 2,182 | 1,608 | 36 |
| Professional Hygiene | 3,978 | 2,701 | 47 | 1,417 | 679 | 109 |
| Other | -1,054 | -789 | -305 | -197 | ||
| Total1 | 11,942 | 12,828 | -7 | 3,794 | 2,827 | 34 |
1Excluding items affecting comparability; for amounts see page 13.
| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Health & Medical | 2,292 | 3,832 | -40 | 822 | 1,038 | -21 |
| Consumer Goods | 4,981 | 6,328 | -21 | 966 | 1,804 | -46 |
| Professional Hygiene | 3,397 | 2,512 | 35 | 1,259 | 754 | 67 |
| Other | -1,503 | -1,554 | -584 | -390 | ||
| Total | 9,167 | 11,118 | -18 | 2,463 | 3,206 | -23 |



Excluding items affecting comparability
| Change in net sales (%) | |||||
|---|---|---|---|---|---|
| 2212 vs | 22:4 vs | ||||
| Total | 2112 28.2 |
21:4 28.1 |
|||
| Volume | 1.7 | -4.3 | |||
| Price/mix | 14.0 | 18.6 | |||
| Currency | 10.6 | 12.2 | |||
| Acquisitions | 2.0 | 1.7 | |||
| Divestments | -0.1 | -0.1 |
| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | -5 | 33 |
| Volume | 6 | -12 |
| Price/mix | 121 | 205 |
| Raw materials | -89 | -107 |
| Energy | -22 | -4 |
| Currency | 10 | 16 |
| Other | -31 | -65 |
-

Excluding items affecting comparability

Net sales increased 28.2% to SEK 156,173m (121,867). Sales growth, including organic sales growth and acquisitions, amounted to 17.7%. Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, amounted to 15.7%, of which volume accounted for 1.7% and price/mix for 14.0%. Organic sales growth in mature markets amounted to 17.5% and in emerging markets to 12.8%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 10.6%. Acquisitions increased net sales by 2.0%. Divestments reduced net sales by 0.1%.
The Group's gross margin was 23.8% (28.8). The Group's adjusted gross margin decreased by 3.8 percentage points to 25.1% (28.9). Higher costs for raw materials, energy and distribution reduced the margin by 11.7 percentage points. The margin was positively impacted by higher selling prices, higher volumes and a better mix. Continuous cost savings amounted to SEK -956m. Higher cost inflation had a negative impact on reported cost savings.
The Group's EBITA margin was 7.0% (11.5). The Group's adjusted EBITA margin decreased 2.8 percentage points to 8.4% (11.2). Sales costs, including marketing costs, were higher but decreased as a share of net sales.
Operating profit before amortization of acquisition-related intangible assets (EBITA) amounted to SEK 10,887m (14,051). Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) decreased 5% (16% excluding currency translation effects, acquisitions and divestments) to SEK 13,058m (13,680).
Items affecting comparability amounted to SEK -2,463m (371). Costs were mainly attributable to the impairment of assets in Russia of SEK -1,718m. Restructuring costs amounted to SEK -592m. Other amounted to SEK -153m.
Financial items increased to SEK -1,370m (-662), on account of higher average net debt and higher interest rates.
Profit before tax amounted to SEK 8,109m (12,537). Adjusted profit before tax decreased 13% (24% excluding currency translation effects, acquisitions and divestments) to SEK 10,572m (12,166).
The tax expense was SEK 2,045m (2,727). The tax expense, excluding effects of items affecting comparability, was SEK 2,245m (2,803).
Profit for the period decreased 38% (49% excluding currency translation effects, acquisitions and divestments) to SEK 6,064m (9,810). Adjusted profit for the period decreased 11% (22% excluding currency translation effects, acquisitions and divestments) to SEK 8,327m (9,363).
Earnings per share were SEK 7.93 (12.27). The adjusted earnings per share were SEK 12.28 (12.50).
Return on capital employed was 8.1% (12.3). The adjusted return on capital employed was 9.7% (12.0). Return on equity was 8.1% (15.0). The adjusted return on equity was 11.1% (14.3).
Net sales increased 28.1% to SEK 43,834m (34,226). Sales growth, including organic sales growth and acquisitions, amounted to 16.0%. Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, amounted to 14.3%, of which volume accounted for -4.3% and price/mix for 18.6%. Organic sales growth in mature markets amounted to 17.9% and in emerging markets to 8.9%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 12.2%. Acquisitions increased net sales by 1.7%. Divestments reduced net sales by 0.1%.
The Group's gross margin was 25.2% (24.9). The Group's adjusted gross margin increased by 0.7 of a percentage point to 25.9% (25.2). Higher costs for raw materials, energy (including energy subsidies) and distribution reduced the margin by 9.5 percentage points. Lower volumes also had a negative impact. The margin was positively impacted by higher selling prices. Continuous cost savings amounted to SEK -551m. Higher cost inflation had a negative impact on reported cost savings.

The Group's EBITA margin was 8.6% (8.8). The Group's adjusted EBITA margin increased 0.3 of a percentage point to 9.3% (9.0). Sales costs, including marketing costs, were higher and increased as a share of net sales.
Operating profit before amortization of acquisition-related intangible assets (EBITA) amounted to SEK 3,790m (3,004). Adjusted operating profit before amortization of acquisition-related intangible assets (adjusted EBITA) increased by 33% (17% excluding currency translation effects, acquisitions and divestments) to SEK 4,084m (3,077).
Profit for the period increased by 1% (14% decrease excluding currency translation effects, acquisitions and divestments) to SEK 2,246m (2,218). Profit for the period increased by 10% (5% decrease excluding currency translation effects, acquisitions and divestments) to SEK 2,490m (2,264).
Earnings per share were SEK 3.15 (2.82). The adjusted earnings per share were SEK 3.78 (3.14).
Return on capital employed was 10.5% (9.8). The adjusted return on capital employed was 11.4% (10.1). Return on equity was 11.2% (13.3). The adjusted return on equity was 12.4% (13.5).
The operating cash surplus amounted to SEK 20,974m (20,471). The cash flow effect of changes in working capital was SEK -3,684m (-844). Working capital was negatively impacted by an increase in trade receivables as a result of higher sales and increased inventory value due to higher raw material prices. Investments in non-current assets, net, excluding investments in operating assets through leases, amounted to SEK -6,875m (-7,304). Operating cash flow before investments in operating assets through leases amounted to SEK 9,714m (11,598). Operating cash flow was SEK 9,167m (11,118).
Financial items increased to SEK -1,370m (-662), on account of higher average net debt and higher interest rates.
Tax payments had an impact on cash flow of SEK -2,426m (-3,634).
The net sum of acquisitions and divestments was SEK -4,955m (-11,800). Net cash flow totaled SEK -4,852m (-10,193).
Net debt increased by SEK 7,436m during the period to SEK 62,869m. Excluding pension liabilities, net debt amounted to SEK 62,163m. Net cash flow increased net debt by SEK 4,852m. Fair value measurement of pension assets and updated assumptions and assessments that affect measurement of the net pension liability, together with fair value measurement of financial instruments, reduced net debt by SEK 2,281m. Exchange rate movements increased net debt by SEK 4,303m. Investments in non-operating assets through leases increased net debt by SEK 562m. The debt/equity ratio was 0.82 (0.81). Excluding pension liabilities, the debt/equity ratio was 0.81 (0.77). The debt payment capacity was 26% (29). Net debt in relation to EBITDA amounted to 3.13 (2.69). Net debt in relation to adjusted EBITDA amounted to 3.08 (2.77).
The Group's equity increased by SEK 8,057m during the period, to SEK 76,564m. Profit for the period increased equity by SEK 6,064m. Equity decreased due to dividends to shareholders of SEK 5,314m. Equity increased net after tax by SEK 1,637m as a result of fair value measurement of pension assets and updated assumptions and assessments that affect the valuation of the pension liability. Fair value measurement of financial instruments decreased equity by SEK 1,455m after tax. Exchange rate movements, including the effect of hedges of net foreign investments, after tax, increased equity by SEK 7,093m. Other items increased equity by SEK 32m.

A tax expense of SEK 2,245m was reported, excluding items affecting comparability, corresponding to a tax rate of 21.2% for the period. The tax expense including items affecting comparability was SEK 2,045m, corresponding to a tax rate of 25.2% for the period.
The Board of Directors proposes an increase in the dividend of 4% to SEK 7.25 (7.00) per share or SEK 5,092m (4,916). March 31, 2023 is proposed as the record date for the right to receive dividends, and the dividend is expected to be paid on April 5, 2023.

Share of Group, adjusted EBITA 2212



| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | 16.4 | 14.9 |
| Volume | 2.5 | -2.0 |
| Price/mix | 4.8 | 6.6 |
| Currency | 7.3 | 9.0 |
| Acquisitions | 2.3 | 1.7 |
| Divestments | -0.5 | -0.4 |
| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | -24 | -22 |
| Volume | 6 | -4 |
| Price/mix | 29 | 41 |
| Raw materials | -44 | -36 |
| Energy | -3 | -1 |
| Currency | 5 | 7 |
| Other | -17 | -29 |
| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 25,239 | 21,685 | 16 | 6,728 | 5,854 | 15 |
| Adjusted gross profit margin, %* | 36.9 | 42.3 | 35.9 | 39.2 | ||
| Adjusted EBITA* | 2,903 | 3,821 | -24 | 721 | 927 | -22 |
| Adjusted EBITA margin, %* | 11.5 | 17.6 | 10.7 | 15.8 | ||
| Adjusted operating profit* | 2,054 | 3,101 | -34 | 500 | 737 | -32 |
| Adjusted operating margin, %* | 8.1 | 14.3 | 7.4 | 12.6 | ||
| Adjusted return on capital employed, %* | 8.6 | 12.7 | 8.2 | 12.1 | ||
| Operating cash flow | 2,292 | 3,832 | 822 | 1,038 | ||
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 16.4% to SEK 25,239m (21,685). Sales growth, including organic sales growth and acquisitions, amounted to 9.6%. Organic sales growth amounted to 7.3%, of which volume accounted for 2.5% and price/mix for 4.8%. The organic sales growth amounted to 5.5% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 14.5%. Exchange rate effects increased net sales by 7.3%. Acquisitions increased net sales by 2.3%. Divestments reduced net sales by 0.5%.
For Incontinence Products Health Care, with Essity's globally leading TENA brand, organic sales growth amounted to 7.1% due to higher volumes and higher prices. In Medical Solutions, organic sales growth amounted to 7.6% as a result of higher volumes and higher prices. Sales growth was high in Wound Care and Orthopedics.
The adjusted gross margin decreased 5.4 percentage points to 36.9% (42.3). Higher costs for raw materials, energy and distribution had a negative impact on the margin. The margin was positively impacted by higher volumes and higher prices. The adjusted EBITA margin decreased 6.1 percentage points to 11.5% (17.6). Sales costs, including marketing costs, were higher and increased as a share of net sales. Adjusted EBITA decreased 24% (32% excluding currency translation effects, acquisitions and divestments) to SEK 2,903m (3,821).
The operating cash surplus amounted to SEK 3,789m (4,629).
Net sales increased 14.9% to SEK 6,728m (5,854). Sales growth, including organic sales growth and acquisitions, amounted to 6.3%. Organic sales growth amounted to 4.6%, of which volume accounted for -2.0% and price/mix for 6.6%. The organic sales growth amounted to 4.3% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 5.6%. Exchange rate effects increased net sales by 9.0%. Acquisitions increased net sales by 1.7%. Divestments reduced net sales by 0.4%.
For Incontinence Products Health Care, with Essity's globally leading TENA brand, organic sales growth amounted to 3.8% due to higher prices. In Medical Solutions, organic sales growth amounted to 5.7% mainly as a result of higher prices. Sales growth was high in Wound Care and Orthopedics.
-6 The adjusted gross margin decreased 3.3 percentage points to 35.9% (39.2). Higher costs for raw materials, energy and distribution had a negative impact on the margin. Lower volumes also had a negative impact. The margin was positively impacted by higher prices. The adjusted EBITA margin decreased 5.1 percentage points to 10.7% (15.8). Sales costs, including marketing costs, were higher and increased as a share of net sales. Adjusted EBITA decreased 22% (30% excluding currency translation effects, acquisitions and divestments) to SEK 721m (927).






Change in net sales (%)
| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | 28.1 | 29.8 |
| Volume | 0.1 | -4.6 |
| Price/mix | 15.6 | 20.3 |
| Currency | 10.6 | 12.0 |
| Acquisitions | 1.8 | 2.1 |
| Divestments | 0.0 | 0.0 |
| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | -9 | 35 |
| Volume | 2 | -12 |
| Price/mix | 141 | 250 |
| Raw materials | -108 | -146 |
| Energy | -26 | -3 |
| Currency | 10 | 18 |
| Other | -28 | -72 |
| SEKm | 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|---|
| Net sales | 94,841 | 74,040 | 28 | 27,060 | 20,844 | 30 |
| Adjusted gross profit margin, %* | 22.6 | 27.0 | 23.2 | 23.0 | ||
| Adjusted EBITA* | 7,211 | 7,938 | -9 | 2,245 | 1,666 | 35 |
| Adjusted EBITA margin, %* | 7.6 | 10.7 | 8.3 | 8.0 | ||
| Adjusted operating profit* | 6,964 | 7,815 | -11 | 2,182 | 1,608 | 36 |
| Adjusted operating margin, %* | 7.3 | 10.6 | 8.1 | 7.7 | ||
| Adjusted return on capital employed, %* | 9.8 | 12.8 | 11.3 | 10.0 | ||
| Operating cash flow | 4,981 | 6,328 | 966 | 1,804 | ||
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 28.1% to SEK 94,841m (74,040). Sales growth, including organic sales growth and acquisitions, amounted to 17.5%. Organic sales growth amounted to 15.7%, of which volume accounted for 0.1% and price/mix for 15.6%. Organic sales growth amounted to 18.7% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 12.6%. Exchange rate effects increased net sales by 10.6%. Acquisitions increased net sales by 1.8%.
For Incontinence Products Retail, with Essity's globally leading TENA brand, organic sales growth amounted to 10.8%, in Feminine Care to 15.7% and in Baby Care to 1.0%. In Consumer Tissue, organic sales growth amounted to 19.1% and for the Consumer Tissue Private Label Europe division to 35.8%. Prices were higher in all categories. Baby Care was negatively impacted by the discontinuation of the baby diaper business in Latin America.
The adjusted gross margin decreased 4.4 percentage points to 22.6% (27.0). Higher costs for raw materials, energy and distribution had a negative impact on the margin. The margin was positively impacted by higher volumes, higher prices and a better mix. The adjusted EBITA margin decreased 3.1 percentage points to 7.6% (10.7). Sales costs, including marketing costs, were higher but decreased as a share of net sales. Adjusted EBITA decreased 9% (20% excluding currency translation effects, acquisitions and divestments) to SEK 7,211m (7,938).
The operating cash surplus amounted to SEK 11,595m (11,632).
Net sales increased 29.8% to SEK 27,060m (20,844). Sales growth, including organic sales growth and acquisitions, amounted to 17.8%. Organic sales growth amounted to 15.7%, of which volume accounted for -4.6% and price/mix for 20.3%. Organic sales growth amounted to 21.4% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 10.1%. Exchange rate effects increased net sales by 12.0%. Acquisitions increased net sales by 2.1%.
For Incontinence Products Retail, with Essity's globally leading TENA brand, organic sales growth amounted to 10.3%, in Feminine Care to 10.7% and in Baby Care to -6.5%. In Consumer Tissue, organic sales growth amounted to 20.9% and for the Consumer Tissue Private Label Europe division to 48.7%. Prices were higher in all categories. Volumes in Baby Care were negatively impacted by the discontinuation of the baby diaper business in Latin America.
-6 The adjusted gross margin increased 0.2 percentage points to 23.2% (23.0). Higher costs for raw materials, energy and distribution had a negative impact on the margin. Lower volumes also had a negative impact. The margin was positively impacted by higher prices. The adjusted EBITA margin increased 0.3 percentage points to 8.3% (8.0). Sales costs, including marketing costs, were higher but decreased as a share of net sales. Adjusted EBITA increased 35% (17% excluding currency translation effects, acquisitions and divestments) to SEK 2,245m (1,666).






Change in net sales (%)
| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | 38.1 | 33.9 |
| Volume | 5.8 | -5.4 |
| Price/mix | 17.1 | 23.7 |
| Currency | 13.1 | 15.1 |
| Acquisitions | 2.1 | 0.5 |
| Divestments | 0.0 | 0.0 |
| 2212 vs 2112 |
22:4 vs 21:4 |
|
|---|---|---|
| Total | 48 | 109 |
| Volume | 15 | -20 |
| Price/mix | 156 | 264 |
| Raw materials | -73 | -77 |
| Energy | -31 | -11 |
| Currency | 15 | 21 |
| Other | -34 | -68 |
| 2212 | 2112 | % | 2022:4 | 2021:4 | % |
|---|---|---|---|---|---|
| 36,114 | 26,143 | 38 | 10,077 | 7,527 | 34 |
| 23.1 | 23.3 | 26.1 | 20.4 | ||
| 3,998 | 2,710 | 48 | 1,423 | 681 | 109 |
| 11.1 | 10.4 | 14.1 | 9.0 | ||
| 3,978 | 2,701 | 47 | 1,417 | 679 | 109 |
| 11.0 | 10.3 | 14.1 | 9.0 | ||
| 14.5 | 11.8 | 19.5 | 11.1 | ||
| 3,397 | 2,512 | 1,259 | 754 | ||
*) Excluding restructuring costs, which are reported as items affecting comparability outside of the business area.
Net sales increased 38.1% to SEK 36,114m (26,143). Sales growth, including organic sales growth and acquisitions, amounted to 25.0%. Organic sales growth amounted to 22.9%, of which volume accounted for 5.8% and price/mix for 17.1%. Organic sales growth amounted to 25.6% in mature markets. In emerging markets, which accounted for 19% of net sales, organic sales growth was 13.2%. Exchange rate effects increased net sales by 13.1%. Acquisitions increased net sales by 2.1%.
The adjusted gross margin decreased 0.2 of a percentage point to 23.1% (23.3). Higher costs for raw materials, energy and distribution had a negative impact on the margin. The margin was positively impacted by higher prices, a better mix and higher volumes. The adjusted EBITA margin increased 0.7 percentage points to 11.1% (10.4). Sales costs, including marketing costs, were higher but decreased as a share of net sales. Adjusted EBITA increased 48% (33% excluding currency translation effects, acquisitions and divestments) to SEK 3,998m (2,710).
The operating cash surplus amounted to SEK 6,386m (4,782).
Net sales increased 33.9% to SEK 10,077m (7,527). Sales growth, including organic sales growth and acquisitions, amounted to 18.8%. Organic sales growth amounted to 18.3%, of which volume accounted for -5.4% and price/mix for 23.7%. Organic sales growth amounted to 22.8% in mature markets. In emerging markets, which accounted for 18% of net sales, organic sales growth was 3.3%. Exchange rate effects increased net sales by 15.1%. Acquisitions increased net sales by 0.5%.
The adjusted gross margin increased by 5.7 percentage points to 26.1% (20.4). Higher costs for raw materials, energy and distribution had a negative impact on the margin. Lower volumes also had a negative impact. The margin was positively impacted by higher prices. The adjusted EBITA margin increased 5.1 percentage points to 14.1% (9.0). Sales costs, including marketing costs, were higher and increased as a share of net sales. Adjusted EBITA increased 109% (89% excluding currency translation effects, acquisitions and divestments) to SEK 1,423m (681).
-6

| December 31, 2022 | Class A | Class B | Total |
|---|---|---|---|
| Registered number of shares | 61,208,914 | 641,133,575 | 702,342,489 |
At the end of the period, the proportion of Class A shares was 8.7%. In the fourth quarter, 80,000 Class A shares were converted to Class B shares at the request of shareholders. The total number of votes in the company amounts to 1,253,222,715.
Essity's Annual Report for 2022 is intended to be published during the week starting February 27, 2023. In 2023, interim reports will be published on April 27, July 20 and October 26.
Essity's Annual General Meeting will be held in Stockholm on March 29, 2023.
In conjunction with publication, a telephone and web presentation will be held at 09:00 CET, where President and CEO Magnus Groth will present and answer questions.
Date: Thursday, January 26, 2023 Time: 09:00 CET Link to Web presentation:https://essity.videosync.fi/2023-01-26 Telephone: UK: +44 (0) 33 055 102 00, USA: +1 212 999 66 59, SWE: +46 8 505 204 24. Please call in well in advance of the start of the presentation. Indicate: "Essity". The presentation of the year-end report will also be available on LinkedIn and Twitter.
Stockholm January 26, 2023 Essity Aktiebolag (publ)
Magnus Groth President and CEO
Fredrik Rystedt, CFO and Executive Vice President, +46 8 788 51 31 Johan Karlsson, Vice President Investor Relations, Group Function Finance, +46 70 511 15 81 Joséphine Edwall Björklund, Chief Communication Officer, Group Function Communications, +46 8 788 52 34 Per Lorentz, Vice President Corporate Communications, Group Function Communications, +46 73 313 30 55
This report has not been reviewed by the company's auditors.
This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Media Relations Director, at 07:00 CET on January 26, 2023.

| Net sales 43,834 34,226 40,109 156,173 121,867 Cost of goods sold1,2 -32,499 -25,617 -30,625 -117,046 -86,628 Items affecting comparability - cost of goods sold2 -302 -82 -131 -1,899 -146 Gross profit 11,033 8,527 9,353 37,228 35,093 Sales, general and administration1,2 -7,259 -5,538 -6,500 -26,107 -21,617 Items affecting comparability - sales, general and administration2 8 9 -75 -272 517 Share of profits of associates and joint ventures 8 6 6 38 58 Operating profit before amortization of acquisition-related intangible assets (EBITA) 3,790 3,004 2,784 10,887 14,051 Amortization of acquisition-related intangible assets -290 -250 -287 -1,116 -852 Items affecting comparability - Acquisition-related intangible assets2 -29 0 -6 -292 0 Operating profit 3,471 2,754 2,491 9,479 13,199 Financial items -570 -190 -368 -1,370 -662 Profit before tax 2,901 2,564 2,123 8,109 12,537 Income taxes -655 -346 -499 -2,045 -2,727 Profit for the period 2,246 2,218 1,624 6,064 9,810 Earnings attributable to: Owners of the Parent company 2,209 1,982 1,567 5,567 8,620 Non-controlling interests 37 236 57 497 1,190 Earnings per share - owners of the Parent company Earnings per share before and after dilution effects, SEK 3.15 2.82 2.23 7.93 12.27 Average numbers of shares before and after dilution, million 702.3 702.3 702.3 702.3 702.3 1Of which, depreciation and amortization -2,190 -1,926 -2,162 -8,407 -7,214 2Of which, impairment -350 -75 -151 -2,191 -177 Gross margin 25.2 24.9 23.3 23.8 28.8 EBITA margin 8.6 8.8 6.9 7.0 11.5 Operating margin 7.9 8.0 6.2 6.1 10.8 Financial net margin -1.3 -0.6 -0.9 -0.9 -0.5 Profit margin 6.6 7.4 5.3 5.2 10.3 Income taxes -1.5 -1.0 -1.2 -1.3 -2.2 Net margin 5.1 6.4 4.1 3.9 8.1 Adjusted, excluding items affecting comparability: Gross margin 25.9 25.2 23.6 25.1 28.9 EBITA margin 9.3 9.0 7.5 8.4 11.2 Operating margin 8.7 8.3 6.7 7.6 10.5 Financial net margin -1.3 -0.6 -0.9 -0.9 -0.5 Profit margin 7.4 7.7 5.8 6.7 10.0 |
SEKm | 2022:4 | 2021:4 | 2022:3 | 2212 | 2112 |
|---|---|---|---|---|---|---|
| Income taxes | -1.7 | -1.1 | -1.3 | -1.4 | -2.3 | |
| Net margin 5.7 6.6 4.5 5.3 7.7 |

| SEKm | 2022:4 | 2021:4 | 2022:3 | 2212 | 2112 |
|---|---|---|---|---|---|
| Profit for the period | 2,246 | 2,218 | 1,624 | 6,064 | 9,810 |
| Other comprehensive income for the period | |||||
| Items that will not be reclassified to the income statement | |||||
| Actuarial gains/losses on defined benefit pension plans | -19 | -105 | 56 | 2,299 | -148 |
| Fair value through other comprehensive income | 0 | -1 | -2 | -16 | 0 |
| Income tax attributable to components in other comprehensive income | -107 | -132 | 5 | -659 | -13 |
| -126 | -238 | 59 | 1,624 | -161 | |
| Items that have been or may be reclassified subsequently to the income statement | |||||
| Cash flow hedges | |||||
| Result from remeasurement of derivatives recognized in equity | -7,787 | 380 | 5,202 | 3,110 | 4,142 |
| Transferred to profit or loss for the period | -1,121 | -896 | -1,908 | -5,252 | -1,363 |
| Translation differences in foreign operations | -3,233 | 1,752 | 3,969 | 8,311 | 5,480 |
| Gains/losses from hedges of net investments in foreign operations | 808 | -254 | -827 | -1,397 | -1,012 |
| Other comprehensive income from associates companies | 0 | 3 | 0 | 0 | 15 |
| Income tax attributable to components in other comprehensive income | 2,213 | 192 | -701 | 848 | -539 |
| -9,120 | 1,177 | 5,735 | 5,620 | 6,723 | |
| Other comprehensive income for the period, net of tax | -9,246 | 939 | 5,794 | 7,244 | 6,562 |
| Total comprehensive income for the period | -7,000 | 3,157 | 7,418 | 13,308 | 16,372 |
| Total comprehensive income attributable to: | |||||
| Owners of the Parent company | -6,682 | 2,572 | 7,173 | 12,338 | 14,294 |
| Non-controlling interests | -318 | 585 | 245 | 970 | 2,078 |
| SEKm | 2212 | 2112 |
|---|---|---|
| Equity attributable to owners of the Parent company | ||
| Value, January 1 | 59,874 | 54,352 |
| Total comprehensive income for the period | 12,338 | 14,294 |
| Dividend | -4,916 | -4,741 |
| Acquisition of non-controlling interests | -10 | -4,042 |
| Private placement to non-controlling interests | 17 | 13 |
| Transferred to cost of hedged investments | 31 | 1 |
| Revaluation effect upon acquisition of non-controlling interests | 12 | -3 |
| Value, December 31 | 67,346 | 59,874 |
| Non-controlling interests | ||
| Value, January 1 | 8,633 | 8,990 |
| Total comprehensive income for the period | 970 | 2,078 |
| Dividend | -398 | -528 |
| Private placement to non-controlling interests | 16 | 12 |
| Acquisition of non-controlling interests | -3 | -1,919 |
| Value, December 31 | 9,218 | 8,633 |
| Total equity, value December 31 | 76,564 | 68,507 |

| SEKm | 2212 | 2112 |
|---|---|---|
| Operating cash surplus | 20,974 | 20,471 |
| Change in working capital | -3,684 | -844 |
| Investment in non-current assets, net | -6,875 | -7,304 |
| Restructuring costs, etc. | -701 | -725 |
| Operating cash flow before investments in operating assets through leases | 9,714 | 11,598 |
| Investments in operating assets through leases | -547 | -480 |
| Operating cash flow | 9,167 | 11,118 |
| Financial items | -1,370 | -662 |
| Income taxes paid | -2,426 | -3,634 |
| Other | 9 | 72 |
| Cash flow from current operations | 5,380 | 6,894 |
| Acquisitions of Group companies and other operations | -4,955 | -11,813 |
| Divestments of Group companies and other operations | 0 | 13 |
| Cash flow before transactions with shareholders | 425 | -4,906 |
| Private placement to non-controlling interests | 35 | 25 |
| Dividend to non-controlling interests | -396 | -571 |
| Dividend | -4,916 | -4,741 |
| Net cash flow | -4,852 | -10,193 |
| Net debt at the start of the period | -55,433 | -42,688 |
| Net cash flow | -4,852 | -10,193 |
| Remeasurements to equity | 2,281 | -147 |
| Investments in non-operating assets through leases | -562 | -385 |
| Translation differences | -4,303 | -2,020 |
| Net debt at the end of the period | -62,869 | -55,433 |
| Debt/equity ratio | 0.82 | 0.81 |
| Debt payment capacity, % | 26 | 29 |
| Net debt/EBITDA | 3.13 | 2.69 |
| Net debt/Adjusted EBITDA | 3.08 | 2.77 |

| Operating activities Operating profit 9,479 13,199 Adjustment for non-cash items1 11,341 7,212 Interest paid -811 -724 Interest received 171 91 Other financial items -658 -39 Change in liabilities relating to restructuring programs, etc. -538 -594 Paid tax -2,426 -3,634 Cash flow from operating activities before changes in working capital 16,558 15,511 Cash flow from changes in working capital Change in inventories -7,380 -1,047 Change in operating receivables -3,817 -2,084 Change in operating liabilities 7,513 2,287 Cash flow from operating activities 12,874 14,667 Investing activities Acquisitions of Group companies and other operations -4,797 -4,427 Divestments of Group companies and other operations 0 16 Investments in intangible assets and property, plant and equipment -6,898 -7,301 Sale of property, plant and equipment 74 54 Investment in current financial assets, etcetera -2,828 -418 Paid interest capitalized in intangible asset and property, plant and equipment -51 -57 Cash flow from investing activities -14,500 -12,133 Financing activities Private placement to non-controlling interests 35 25 Acquisition of non-controlling interests -14 -5,961 Dividend -4,916 -4,741 Proceeds from borrowings 18,214 19,444 Repayment of borrowings -11,115 -12,003 Dividend to non-controlling interests -396 -571 Cash flow from financing activities 1,808 -3,807 Cash flow for the period 182 -1,273 Cash and cash equivalents at the beginning of the period 3,904 4,982 Translation differences in cash and cash equivalents 202 195 Cash and cash equivalents at the end of the period 4,288 3,904 Cash flow from operating activities per share, SEK 18.30 20.88 Reconciliation with consolidated operating cash flow statement Cash flow for the period 182 -1,273 Paid/unpaid financial receivable upon divestment of Group company 0 -18 Repayment of borrowings 11,115 12,003 Proceeds from borrowings -18,214 -19,444 Loans granted to external parties 2,828 418 Investment in operating assets through leases -547 -480 Net debt in acquired and divested operations -144 -1,410 Accrued interest -72 10 Other 0 1 Net cash flow according to consolidated operating cash flow statement -4,852 -10,193 1) Adjustment for non-cash items Depreciation/amortization and impairment of non-current assets 10,598 7,391 Gain/loss on asset sales 30 13 Change in provision for ongoing competition case 0 -54 Depreciation of prepaid selling expenses 465 400 Gain/loss on divestments and liquidation 2 21 Non-cash items relating to efficiency program 84 -43 Revaluation effect of previously owned holding upon acquisition 0 -706 Other 162 190 |
SEKm | 2212 | 2112 |
|---|---|---|---|
| Total | 11,341 | 7,212 |

| SEKm | December 31, 2022 | December 31, 2021 |
|---|---|---|
| ASSETS | ||
| Non-current assets | ||
| Goodwill | 44,786 | 37,803 |
| Other intangible assets | 25,346 | 21,806 |
| Property, plant and equipment | 62,898 | 58,918 |
| Investments in associates and joint ventures | 291 | 239 |
| Shares and participations | 6 | 7 |
| Surplus in funded pension plans | 1,965 | 1,439 |
| Non-current financial assets | 123 | 412 |
| Deferred tax assets | 2,545 | 2,012 |
| Other non-current assets | 1,620 | 1,411 |
| Total non-current assets | 139,580 | 124,047 |
| Current Assets | ||
| Inventories | 28,888 | 19,339 |
| Trade receivables | 25,990 | 19,871 |
| Current tax assets | 1,152 | 952 |
| Other current receivables | 5,761 | 5,787 |
| Current financial assets | 4,941 | 1,150 |
| Cash and cash equivalents | 4,288 | 3,904 |
| Total current assets | 71,020 | 51,003 |
| Total assets | 210,600 | 175,050 |
| EQUITY AND LIABILITIES | ||
| Equity | ||
| Share capital | 2,350 | 2,350 |
| Reserves | 11,473 | 6,416 |
| Retained earnings | 53,523 | 51,108 |
| Equity attributable to owners of the Parent company | 67,346 | 59,874 |
| Non-controlling interests | 9,218 | 8,633 |
| Total equity | 76,564 | 68,507 |
| Non-current liabilities | ||
| Non-current financial liabilities | 58,242 | 47,443 |
| Provisions for pensions | 2,671 | 4,149 |
| Deferred tax liabilities | 8,718 | 7,574 |
| Other non-current provisions | 491 | 396 |
| Other non-current liabilities | 1,196 | 86 |
| Total non-current liabilities | 71,318 | 59,648 |
| Current liabilities | ||
| Current financial liabilities | 13,273 | 10,746 |
| Trade payables | 25,644 | 18,030 |
| Current tax liabilities | 1,589 | 1,576 |
| Current provisions | 1,217 | 736 |
| Other current liabilities | 20,995 | 15,807 |
| Total current liabilities | 62,718 | 46,895 |
| Total liabilities | 134,036 | 106,543 |
| Total equity and liabilities | 210,600 | 175,050 |

| SEKm | December 31, 2022 | December 31, 2021 |
|---|---|---|
| Debt/equity ratio | 0.82 | 0.81 |
| Equity/assets ratio | 32% | 34% |
| Equity | 76,564 | 68,507 |
| Equity per share, SEK | 109 | 98 |
| Return on equity | 8.1% | 15.0% |
| Return on equity excluding items affecting comparability | 11.1% | 14.3% |
| Capital employed | 139,433 | 123,940 |
| - of which working capital | 14,033 | 11,157 |
| Return on capital employed* | 8.1% | 12.3% |
| Return on capital employed* excluding items affecting comparability | 9.7% | 12.0% |
| Net debt | 62,869 | 55,433 |
| Provisions for restructuring costs are included in the balance sheet as follows | ||
| -Other non-current provisions | 105 | 96 |
| -Other current provisions | 213 | 160 |
*) rolling 12 months

| SEKm | 2212 | 2112 | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 | 2021:3 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 25,239 | 21,685 | 6,728 | 6,544 | 6,145 | 5,822 | 5,854 | 5,572 |
| Consumer Goods | 94,841 | 74,040 | 27,060 | 23,825 | 22,970 | 20,986 | 20,844 | 18,310 |
| Professional Hygiene | 36,114 | 26,143 | 10,077 | 9,733 | 8,811 | 7,493 | 7,527 | 7,260 |
| Other | -21 | -1 | -31 | 7 | 3 | 0 | 1 | 3 |
| Total | 156,173 | 121,867 | 43,834 | 40,109 | 37,929 | 34,301 | 34,226 | 31,145 |
| (%) | 2212 | 2112 | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 | 2021:3 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 7.3 | 5.4 | 4.6 | 7.6 | 7.9 | 9.5 | 6.9 | 7.3 |
| Consumer Goods | 15.7 | 1.8 | 15.7 | 17.6 | 17.9 | 11.5 | 5.7 | 2.9 |
| Professional Hygiene | 22.9 | 5.7 | 18.3 | 19.9 | 26.1 | 29.8 | 16.4 | 20.7 |
| Total | 15.7 | 3.3 | 14.3 | 16.3 | 17.8 | 14.6 | 8.0 | 7.4 |
| (business area reporting) | ||||||||
|---|---|---|---|---|---|---|---|---|
| (%) | 2212 | 2112 | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 | 2021:3 |
| Health & Medical | 9.6 | 6.5 | 6.3 | 9.9 | 10.9 | 11.7 | 8.2 | 8.6 |
| Consumer Goods | 17.5 | 2.8 | 17.8 | 18.4 | 20.0 | 13.8 | 7.8 | 5.0 |
| Professional Hygiene | 25.0 | 7.5 | 18.8 | 20.3 | 30.2 | 34.1 | 20.2 | 24.3 |
| Total | 17.7 | 4.5 | 16.0 | 17.3 | 20.6 | 17.3 | 10.3 | 9.7 |
| 2212 | 2112 | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 | 2021:3 |
|---|---|---|---|---|---|---|---|
| 2,903 | 3,821 | 721 | 673 | 673 | 836 | 927 | 1,024 |
| 7,211 | 7,938 | 2,245 | 1,460 | 1,861 | 1,645 | 1,666 | 1,832 |
| 3,998 | 2,710 | 1,423 | 1,096 | 916 | 563 | 681 | 900 |
| -1,054 | -789 | -305 | -239 | -292 | -218 | -197 | -170 |
| 13,058 | 13,680 | 4,084 | 2,990 | 3,158 | 2,826 | 3,077 | 3,586 |
| SEKm | 2212 | 2112 | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 | 2021:3 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 2,054 | 3,101 | 500 | 456 | 463 | 635 | 737 | 849 |
| Consumer Goods | 6,964 | 7,815 | 2,182 | 1,395 | 1,801 | 1,586 | 1,608 | 1,774 |
| Professional Hygiene | 3,978 | 2,701 | 1,417 | 1,091 | 911 | 559 | 679 | 898 |
| Other | -1,054 | -789 | -305 | -239 | -293 | -217 | -197 | -170 |
| Total adjusted operating profit1 | 11,942 | 12,828 | 3,794 | 2,703 | 2,882 | 2,563 | 2,827 | 3,351 |
| Financial items | -1,370 | -662 | -570 | -368 | -224 | -208 | -190 | -137 |
| Profit before tax1 | 10,572 | 12,166 | 3,224 | 2,335 | 2,658 | 2,355 | 2,637 | 3,214 |
| Income taxes | -2,245 | -2,803 | -734 | -509 | -575 | -427 | -373 | -808 |
| Net profit for the period2 | 8,327 | 9,363 | 2,490 | 1,826 | 2,083 | 1,928 | 2,264 | 2,406 |
| 1Excluding items affecting comparability before tax amounting to: | -2,463 | 371 | -323 | -212 | -515 | -1,413 | -73 | 524 |
| 2Excluding items affecting comparability after tax amounting to: | -2,263 | 447 | -244 | -202 | -410 | -1,407 | -46 | 559 |
| (%) | 2212 | 2112 | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 | 2021:3 |
|---|---|---|---|---|---|---|---|---|
| Health & Medical | 11.5 | 17.6 | 10.7 | 10.3 | 11.0 | 14.4 | 15.8 | 18.4 |
| Consumer Goods | 7.6 | 10.7 | 8.3 | 6.1 | 8.1 | 7.8 | 8.0 | 10.0 |
| Professional Hygiene | 11.1 | 10.4 | 14.1 | 11.3 | 10.4 | 7.5 | 9.0 | 12.4 |
| Total | 8.4 | 11.2 | 9.3 | 7.5 | 8.3 | 8.2 | 9.0 | 11.5 |

| SEKm | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 |
|---|---|---|---|---|---|
| Net sales | 43,834 | 40,109 | 37,929 | 34,301 | 34,226 |
| Cost of goods sold | -32,499 | -30,625 | -28,321 | -25,601 | -25,617 |
| Items affecting comparability - cost of goods sold | -302 | -131 | -383 | -1,083 | -82 |
| Gross profit | 11,033 | 9,353 | 9,225 | 7,617 | 8,527 |
| Sales, general and administration | -7,259 | -6,500 | -6,460 | -5,888 | -5,538 |
| Items affecting comparability - sales, general and administration | 8 | -75 | -125 | -80 | 9 |
| Share of profits of associates and joint ventures | 8 | 6 | 10 | 14 | 6 |
| EBITA | 3,790 | 2,784 | 2,650 | 1,663 | 3,004 |
| Amortization of acquisition-related intangible assets | -290 | -287 | -276 | -263 | -250 |
| Items affecting comparability - acquisition-related intangible assets | -29 | -6 | -7 | -250 | 0 |
| Operating profit | 3,471 | 2,491 | 2,367 | 1,150 | 2,754 |
| Financial items | -570 | -368 | -224 | -208 | -190 |
| Profit before tax | 2,901 | 2,123 | 2,143 | 942 | 2,564 |
| Income taxes | -655 | -499 | -470 | -421 | -346 |
| Net profit for the period | 2,246 | 1,624 | 1,673 | 521 | 2,218 |
| SEKm | 2212 | 2112 |
|---|---|---|
| Administrative expenses | -755 | -734 |
| Other operating income | 237 | 312 |
| Operating loss | -518 | -422 |
| Financial items | -2,194 | 2,702 |
| Profit before tax | -2,712 | 2,280 |
| Appropriations and income taxes | 316 | -169 |
| Profit for the period | -2,396 | 2,111 |
| SEKm | December 31, 2022 | December 31, 2021 |
|---|---|---|
| Intangible assets | 0 | 0 |
| Property, plant and equipment | 12 | 13 |
| Financial non-current assets | 176,780 | 177,279 |
| Total non-current assets | 176,792 | 177,292 |
| Total current assets | 3,046 | 852 |
| Total assets | 179,838 | 178,144 |
| Restricted equity | 2,350 | 2,350 |
| Non-restricted equity | 76,246 | 83,559 |
| Total equity | 78,596 | 85,909 |
| Untaxed reserves | 195 | 6 |
| Provisions | 846 | 880 |
| Non-current liabilities | 52,470 | 34,752 |
| Current liabilities | 47,731 | 56,597 |
| Total equity, provisions and liabilities | 179,838 | 178,144 |

This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent company, RFR 2. A few amended accounting standards published by the IASB entered into force on January 1, 2022, following approval by the EU. Essity Aktiebolag (publ) applies these amendments, which have not had any material impact on the Group's or the Parent company's financial statements. All other applied accounting principles and calculation methods correspond to those presented in Essity Aktiebolag's (publ) Annual and Sustainability Report for 2021.
Essity's Board determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Unit Presidents. This means that most operational risks are managed by Essity's business units at the local level, but that they are coordinated when considered necessary. The tools used in this coordination consist primarily of the business units' regular reporting and the annual strategy process, where risks and risk management are a part of the process.
Essity's financial risk management is centralized, as is the Group's internal bank for the Group companies' financial transactions and management of the Group's energy risks. Financial risks are managed in accordance with the Group's finance policy, which is adopted by Essity's Board of Directors and which – together with Essity's energy risk policy – makes up a framework for risk management. Risks are aggregated and monitored on a regular basis to ensure compliance with these guidelines. Essity has also centralized other risk management.
Essity has a staff function for internal audit, which monitors compliance with the Group's policies in the organization.
Essity's risk exposure and risk management are described on pages 35–40 of Essity's Annual and Sustainability Report for 2021. No significant changes have taken place that have affected the reported risks.
Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim and year-end reports.
The war in Ukraine has created an uncertain situation for the health and safety of several of our employees. Furthermore, the global situation has also been negatively affected and, for example, energy prices in Europe have increased drastically. The higher energy prices impact Essity's earnings.
The company's assets in Russia have been impaired by approximately SEK 1.7bn. Work is ongoing to exit the Russian market. In 2022, Essity's net sales in Russia amounted to approximately SEK 3.6bn, corresponding to about 2% of total consolidated net sales in 2022. Net assets in Russia amounted to approximately SEK 1.4bn following the aforementioned impairment. These assets include cash and cash equivalents of SEK 0.9bn. It is not possible to foresee if these cash and cash equivalents will be available outside Russia but it is assumed that they can be used to pay debts in Russia that amount to approximately SEK 0.6bn. Other assets consist of inventory of approximately SEK 500m, trade receivables of approximately SEK 500m and other receivables of approximately SEK 100m. Essity has 1,400 employees in Russia and three production plants.
Essity's net sales in Ukraine amounted to less than 1% of total consolidated net sales in 2022.
In the fourth quarter of 2022, a lawsuit was served by Spanish authorities against, among other companies, Essity for alleged participation in collusion between incontinence product producers between 1996 and 2014. Essity has denied liability.

Distribution by level for measurement at fair value
| SEKm | Carrying amount in the balance sheet |
Measured at fair value through profit or loss |
Derivatives used for hedge accounting |
Financial assets measured at fair value through OCI |
Financial liabilities measured at amortized cost |
Of which fair value by level1 |
|
|---|---|---|---|---|---|---|---|
| December 31, 2022 | 1 | 2 | |||||
| Derivatives | 4,416 | 1,631 | 2,785 | - | - | - | 4,416 |
| Non-current financial assets | 92 | - | - | 92 | - | 92 | - |
| Total assets | 4,508 | 1,631 | 2,785 | 92 | - | 92 | 4,416 |
| Derivatives | 6,126 | 765 | 5,361 | - | - | - | 6,126 |
| Financial liabilities Current financial liabilities |
12,501 | 4,489 | - | - | 8,012 | - | 4,489 |
| Non-current financial liabilities | 54,090 | 23,763 | - | - | 30,327 | - | 23,763 |
| Total liabilities | 72,717 | 29,017 | 5,361 | - | 38,339 | - | 34,378 |
| December 31, 2021 | |||||||
| Derivatives | 4,784 | 910 | 3,874 | - | - | - | 4,784 |
| Non-current financial assets | 99 | - | - | 99 | - | 99 | - |
| Total assets | 4,883 | 910 | 3,874 | 99 | - | 99 | 4,784 |
| Derivatives Financial liabilities |
1,578 | 633 | 945 | - | - | - | 1,578 |
| Current financial liabilities | 9,838 | 14 | - | - | 9,824 | - | 14 |
| Non-current financial liabilities | 47,056 | 20,386 | - | - | 26,670 | - | 20,386 |
| Total liabilities | 58,472 | 21,033 | 945 | - | 36,494 | - | 21,978 |
1 No financial instruments have been classified to level 3
The total fair value of the above financial liabilities, excluding lease liabilities, is SEK 64,324m (53,925). The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and noncurrent liabilities is estimated to be equal to their carrying amount.
No transfers between level 1 and 2 were made during the period.
On July 1, 2021, Essity acquired the remaining 63.8% of the shares in the hygiene company Asaleo Care. The purchase price allocation for the acquisition has been finalized. No adjustments were made and the final purchase price allocation is the same as the preliminary purchase price allocation presented in the Annual and Sustainability Report for 2021.
In the final quarter of 2021, Essity acquired the US-based companies Aquacast LLC, active in orthopedics, and Hydrofera, active in wound care. The purchase price allocations for both of these acquisitions were finalized in 2022 and are unchanged compared with the Annual and Sustainability Report for 2021.
On February 2, 2022, Essity acquired the US cleaning and wiping company Legacy Converting, Inc. The company has approximately 30 employees. The final purchase price amounts to USD 39m (SEK 362m) with a potential additional earnout amount of USD 10m (SEK 94m) on a cash and debt-free basis, excluding financial lease liabilities. Since the acquisition, Legacy Converting's reported net sales amounted to SEK 144m, adjusted EBITDA to SEK 24m, and adjusted EBITA to SEK 2m. If Legacy Converting had been consolidated as of January 1, 2022, net sales would have amounted to SEK 154m, adjusted EBITDA to SEK 26m and adjusted EBITA to SEK 2m. The purchase price allocation has not yet been finalized.
On July 7, 2022, Essity announced that the company was acquiring the Australian company Modibodi, a leading leakproof apparel company in Australia, New Zealand and the UK. The purchase price amounted to AUD 141m (approximately SEK 1bn) on a cash and debt-free basis. Modibodi has about 45 employees and is headquartered in Sydney, Australia. Modibodi was consolidated into Essity's accounts from August 1, 2022. Since the acquisition, Modibodi's reported net sales amounted to SEK

169m, adjusted EBITDA to SEK 0m, and adjusted EBITA to SEK -1m. If Modibodi had been consolidated as of January 1, 2022, net sales would have amounted to SEK 398m, adjusted EBITDA to SEK -3m and adjusted EBITA to SEK -4m.
| Purchase price allocation, Modibodi | Preliminary |
|---|---|
| SEKm | |
| Intangible assets | 341 |
| Property, plant and equipment | 4 |
| Other non-current assets | 5 |
| Operating assets | 98 |
| Cash and cash equivalents | 26 |
| Provisions and other non-current liabilities | -102 |
| Net debt excluding cash and cash equivalents | -3 |
| Operating liabilities | -51 |
| Fair value of net assets | 318 |
| Goodwill | 706 |
| Consideration transferred | 1,024 |
| Consideration transferred | -1,024 |
| Cash and cash equivalents in acquired companies | 26 |
| Effect on Group's cash and cash equivalents, acquisition of Group companies and other operations | -998 |
| Acquired net debt excluding cash and cash equivalents | -3 |
| Acquisitions of Group companies and other operations during the period, including net debt assumed | -1,001 |
On July 8, 2022, Essity announced that the company is acquiring 80 percent of Canadian company Knix Wear Inc. ("Knix"), a leading supplier of absorbent menstrual and incontinence underwear. The transaction was finalized on September 1, 2022. The agreement with the seller includes a put/call option to buy/sell the remaining shares in three years at fair value when the option can be redeemed. The amount to be paid if the option is exercised is initially recorded at present value as a liability in Essity's balance sheet. Accordingly, in accounting terms, the acquisition is treated as though 100% of the company had been acquired. The purchase price amounted to CAD 430m (approximately SEK 3.5bn) on a cash and debt-free basis for 80 percent of the company. In 2021, the company reported net sales of CAD 133.6m (approximately SEK 914m), EBITDA of CAD 13.8m (approximately SEK 95m) and EBITA of CAD 13.4m (approximately SEK 92m). Knix has approximately 200 employees and is headquartered in Toronto, Canada. Knix was consolidated into Essity's accounts from September 1, 2022. Since the acquisition, Knix's reported net sales amounted to SEK 493m, adjusted EBITDA to SEK 2m, and adjusted EBITA to SEK -5m. If Knix had been consolidated as of January 1, 2022, net sales would have amounted to SEK 1,351m, adjusted EBITDA to SEK -9m and adjusted EBITA to SEK -20m.
| Purchase price allocation, Knix | Preliminary |
|---|---|
| SEKm | |
| Intangible assets | 1,747 |
| Property, plant and equipment | 79 |
| Other non-current assets | 4 |
| Operating assets | 483 |
| Cash and cash equivalents | 17 |
| Provisions and other non-current liabilities | -457 |
| Net debt excluding cash and cash equivalents | -53 |
| Operating liabilities | -286 |
| Fair value of net assets | 1,534 |
| Goodwill | 2,782 |
| Consideration not transferred, recognized as a liability | -863 |
| Consideration transferred | 3,453 |
| Consideration transferred | -3,453 |
| Cash and cash equivalents in acquired companies | 17 |
| Effect on Group's cash and cash equivalents, acquisition of Group companies and other operations | -3,436 |
| Acquired net debt excluding cash and cash equivalents | -53 |
| Acquisitions of Group companies and other operations during the period, including net debt assumed | -3,489 |

Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.
This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders analyze the company's operations. These non-IFRS measures may differ from similarly titled measures among other companies. Essity's 2021 Annual Report, pages 75–80, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Tables are presented below that show how the performance measures have been calculated.
| SEKm | 2212 | 2112 |
|---|---|---|
| Total assets | 210,600 | 175,050 |
| -Financial assets | -11,317 | -6,905 |
| -Non-current non-interest bearing liabilities | -10,405 | -8,056 |
| -Current non-interest bearing liabilities | -49,445 | -36,149 |
| Capital employed | 139,433 | 123,940 |
| SEKm | 2022:4 | 2022:3 | 2022:2 | 2022:1 | 2021:4 |
|---|---|---|---|---|---|
| Health & Medical | 34,557 | 35,708 | 34,799 | 32,471 | 31,401 |
| Consumer Goods | 76,672 | 81,936 | 73,267 | 68,526 | 66,939 |
| Professional Hygiene | 27,911 | 30,622 | 28,750 | 26,213 | 24,518 |
| Other | 293 | -326 | -950 | 839 | 1,082 |
| Capital employed | 139,433 | 147,940 | 135,866 | 128,049 | 123,940 |
| SEKm | 2212 | 2112 |
|---|---|---|
| Inventories | 28,888 | 19,339 |
| Trade receivables | 25,990 | 19,871 |
| Other current receivables | 5,761 | 5,787 |
| Trade payables | -25,644 | -18,030 |
| Other current liabilities | -20,995 | -15,807 |
| Other | 33 | -3 |
| Working capital | 14,033 | 11,157 |
| SEKm | 2212 | 2112 |
|---|---|---|
| Surplus in funded pension plans | 1,965 | 1,439 |
| Non-current financial assets | 123 | 412 |
| Current financial assets | 4,941 | 1,150 |
| Cash and cash equivalents | 4,288 | 3,904 |
| Financial assets | 11,317 | 6,905 |
| Non-current financial liabilities | 58,242 | 47,443 |
| Provisions for pensions | 2,671 | 4,149 |
| Current financial liabilities | 13,273 | 10,746 |
| Financial liabilities | 74,186 | 62,338 |
| Net debt | 62,869 | 55,433 |

| SEKm | 2212 | 2112 | 2022:4 | 2021:4 |
|---|---|---|---|---|
| Operating profit | 9,479 | 13,199 | 3,471 | 2,754 |
| -Amortization of acquisition-related intangible assets | 1,116 | 852 | 290 | 250 |
| -Depreciation/amortization | 6,217 | 5,424 | 1,621 | 1,424 |
| -Depreciation right-of-use asset | 1,074 | 938 | 279 | 252 |
| -Impairment | 41 | -2 | 30 | -3 |
| -Items affecting comparability - impairment net | 1,858 | 179 | 291 | 78 |
| -Items affecting comparability - impairment of acquisition-related intangible assets | 292 | 0 | 29 | 0 |
| EBITDA | 20,077 | 20,590 | 6,011 | 4,755 |
| -Items affecting comparability excluding depreciation/amortization and impairment | 313 | -550 | 3 | -5 |
| Adjusted EBITDA | 20,390 | 20,040 | 6,014 | 4,750 |
| SEKm | 2212 | 2112 | 2022:4 | 2021:4 |
|---|---|---|---|---|
| Operating profit | 9,479 | 13,199 | 3,471 | 2,754 |
| -Amortization of acquisition-related intangible assets | 1116 | 852 | 290 | 250 |
| -Items affecting comparability - impairment of acquisition-related intangible assets | 292 | 0 | 29 | 0 |
| Operating profit before amortization and impairment of acquisition-related intangible assets (EBITA) |
10,887 | 14,051 | 3,790 | 3,004 |
| EBITA margin (%) | 7.0 | 11.5 | 8.6 | 8.8 |
| -Items affecting comparability - cost of goods sold | 1,899 | 146 | 302 | 82 |
| -Items affecting comparability - sales, general and administration | 272 | -517 | -8 | -9 |
| Adjusted EBITA | 13,058 | 13,680 | 4,084 | 3,077 |
| Adjusted EBITA margin (%) | 8.4 | 11.2 | 9.3 | 9.0 |
| SEKm | 2212 | 2112 | 2022:4 | 2021:4 |
|---|---|---|---|---|
| Health & Medical | ||||
| Operating cash surplus | 3,789 | 4,629 | 960 | 1,137 |
| Change in working capital | -831 | -103 | 38 | 47 |
| Investment in non-current assets, net | -784 | -761 | -244 | -164 |
| Restructuring costs, etc. | 168 | 88 | 69 | 47 |
| Operating cash flow before investments in operating assets through leases | 2,342 | 3,853 | 823 | 1,067 |
| Investment in operating assets through leases | -50 | -21 | -1 | -29 |
| Operating cash flow | 2,292 | 3,832 | 822 | 1,038 |
| Consumer Goods | ||||
| Operating cash surplus | 11,595 | 11,632 | 3,408 | 2,643 |
| Change in working capital | -1,719 | 34 | -811 | 921 |
| Investment in non-current assets, net | -4,103 | -4,581 | -1,320 | -1,335 |
| Restructuring costs, etc. | -373 | -457 | -244 | -205 |
| Operating cash flow before investments in operating assets through leases | 5,400 | 6,628 | 1,033 | 2,024 |
| Investment in operating assets through leases | -419 | -300 | -67 | -220 |
| Operating cash flow | 4,981 | 6,328 | 966 | 1,804 |
| Professional Hygiene | ||||
| Operating cash surplus | 6,386 | 4,782 | 2,023 | 1,233 |
| Change in working capital | -1,062 | -705 | -60 | 141 |
| Investment in non-current assets, net | -1,213 | -941 | -402 | -337 |
| Restructuring costs, etc. | -636 | -466 | -292 | -139 |
| Operating cash flow before investments in operating assets through leases | 3,475 | 2,670 | 1,269 | 898 |
| Investment in operating assets through leases | -78 | -158 | -10 | -144 |
| Operating cash flow | 3,397 | 2,512 | 1,259 | 754 |

| SEKm | 2212 | 2022:4 |
|---|---|---|
| Health & Medical | ||
| Organic sales growth | 1,576 | 267 |
| Acquisitions | 512 | 105 |
| Sales growth including organic sales growth and acquisitions | 2,088 | 372 |
| Divestments | -100 | -26 |
| Exchange rate effect1 | 1,566 | 527 |
| Recognized change | 3,554 | 873 |
| Consumer Goods | ||
| Organic sales growth | 11,629 | 3,282 |
| Acquisitions | 1,347 | 421 |
| Sales growth including organic sales growth and acquisitions | 12,976 | 3,703 |
| Divestments | -8 | 0 |
| Exchange rate effect1 | 7,833 | 2,513 |
| Recognized change | 20,801 | 6,216 |
| Professional Hygiene | ||
| Organic sales growth | 5,975 | 1,375 |
| Acquisitions | 549 | 41 |
| Sales growth including organic sales growth and acquisitions | 6,524 | 1,416 |
| Divestments | 0 | 0 |
| Exchange rate effect1 | 3,447 | 1,134 |
| Recognized change | 9,971 | 2,550 |
| Essity | ||
| Organic sales growth | 19,161 | 4,894 |
| Acquisitions | 2,407 | 566 |
| Sales growth including organic sales growth and acquisitions | 21,568 | 5,460 |
| Divestments | -109 | -27 |
| Exchange rate effect1 | 12,847 | 4,175 |
| Recognized change | 34,306 | 9,608 |
1Consists solely of currency translation effects
In 2022, Essity had sales in approximately 150 countries and the number of employees amounted to about 48,000.
| Net sales 2022 by category Health and Medical |
16% |
|---|---|
| of which Incontinence Products Health Care Medical Solutions |
9% 7% |
| Consumer Goods of which |
61% |
| Incontinence Products Retail | 7% |
| Feminine Care | 7% |
| Baby Care | 6% |
| Consumer Tissue | 41% |
| Professional Hygiene | 23% |
| Europe | 53% |
|---|---|
| Asia | 17% |
| Latin America | 14% |
| North America | 13% |
| Other | 3% |

| Gender distribution at management levels | 2022 |
|---|---|
| Share/number of women on the Board elected by the Annual General Meeting | 40% / 4 (10) |
| Share/number of women on the Board elected by employee organizations | 33% / 1 (3) |
| Share/number of women in the Executive Management Team | 33% / 4 (12) |
| Share/number of women in senior management | 35% / 38 (109) |
| Share/number of women in middle management | 31% / 209 (666) |
Essity's target is that gender distribution at all management levels (Executive Management Team, senior management, middle management) is to be within the interval 40/60% no later than 2025. The target is reported at an aggregate outcome level for the three management levels and the outcome for 2022 was 32%.
Essity's workplace safety target is to achieve a reduction in the total recordable incident rate (TRI-R) of 75% by 2025 compared with 2019. Total recordable incidents (TRI) include lost time accidents (LTA), restricted work cases (RWC) and medical treatment cases (MTC). The outcome for 2022 was a decrease of 39% compared with 2019. The figures pertain to wholly owned companies1) of Essity and exclude sales and administrative offices.
| 2022 | |
|---|---|
| Total recordable incident rate | 4.3 |
| (TRI-R, TRI / millions of hours worked) |
Essity's targets to reduce greenhouse gas emissions were approved by the Science Based Targets initiative in 2018. In terms of energy consumption (Scope 1 and 2), Essity has undertaken to reduce greenhouse gas emissions by 35% by 2030 compared with 2016. The outcome for 2022 was -18% for Scope 1 and 2.
Essity has, moreover, undertaken to reduce greenhouse gas emissions from the most important purchased raw materials, transportation, waste arising from operations and handling at the end of the life cycle of sold products (Scope 3) by 18% by 2030 compared with 2016. The outcome is reported with a delay of one year and will be presented in conjunction with the Annual and Sustainability Report for 2022. Targets and outcomes relate to wholly owned companies.
| 2022 | |
|---|---|
| Scope 1, CO2e, ktons | 1,395 |
| Scope 2, CO2e, ktons | 1,209 |
1) Includes Vinda's production facilities in Malaysia and Taiwan
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.